These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 19100906

  • 1. Minimizing the risk of posttransplant malignancy.
    Campistol JM.
    Transplant Proc; 2008 Dec; 40(10 Suppl):S40-3. PubMed ID: 19100906
    [Abstract] [Full Text] [Related]

  • 2. [Minimizing the risk of cancer in transplant patients].
    Campistol JM.
    G Ital Nefrol; 2010 Dec; 27 Suppl 50():S81-5. PubMed ID: 20922701
    [Abstract] [Full Text] [Related]

  • 3. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 4. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010 Nov; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 6. Conversion to sirolimus in posttransplant renal neoplasms.
    Lopez V, Gutierrez C, Cabello M, Burgos D, Sola E, Gonzalez-Molina M.
    Transplant Proc; 2007 Sep 27; 39(7):2264-6. PubMed ID: 17889158
    [Abstract] [Full Text] [Related]

  • 7. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
    Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, Neylan JF, Korth-Bradley J, Goldberg-Alberts R, Maller ES, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2011 Aug 15; 92(3):303-10. PubMed ID: 21792049
    [Abstract] [Full Text] [Related]

  • 8. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T, Kreis H, Friend P.
    Clin Transplant; 2004 Aug 15; 18(4):446-9. PubMed ID: 15233824
    [Abstract] [Full Text] [Related]

  • 9. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.
    Nephrol Dial Transplant; 2007 May 15; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [Abstract] [Full Text] [Related]

  • 10. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
    Valantine H.
    J Heart Lung Transplant; 2007 Jun 15; 26(6):557-64. PubMed ID: 17543777
    [Abstract] [Full Text] [Related]

  • 11. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B.
    Transpl Int; 2004 Jul 15; 17(6):279-85. PubMed ID: 15221123
    [Abstract] [Full Text] [Related]

  • 12. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
    Kahan BD.
    Transplant Proc; 2008 Dec 15; 40(10 Suppl):S17-20. PubMed ID: 19100899
    [Abstract] [Full Text] [Related]

  • 13. The impact of mTOR inhibitors on the development of malignancy.
    Geissler EK.
    Transplant Proc; 2008 Dec 15; 40(10 Suppl):S32-5. PubMed ID: 19100904
    [Abstract] [Full Text] [Related]

  • 14. Reviewing the evidence for de novo immunosuppression with sirolimus.
    Flechner SM.
    Transplant Proc; 2008 Dec 15; 40(10 Suppl):S25-8. PubMed ID: 19100902
    [Abstract] [Full Text] [Related]

  • 15. Conversion to sirolimus in renal transplant patients with tumors.
    Sánchez-Fructuoso A, Conesa J, Perez Flores I, Ridao N, Calvo N, Prats D, Rodríguez A, Barrientos A.
    Transplant Proc; 2006 Oct 15; 38(8):2451-2. PubMed ID: 17097964
    [Abstract] [Full Text] [Related]

  • 16. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.
    Yakupoglu YK, Buell JF, Woodle S, Kahan BD.
    Transplant Proc; 2006 Mar 15; 38(2):358-61. PubMed ID: 16549120
    [Abstract] [Full Text] [Related]

  • 17. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM, Claesson K, Stallone G, Russ G, Rostaing L, Kreis H, Burke JT, Brault Y, Scarola JA, Neylan JF.
    J Am Soc Nephrol; 2006 Feb 15; 17(2):581-9. PubMed ID: 16434506
    [Abstract] [Full Text] [Related]

  • 18. Minimizing the risk of posttransplant malignancy.
    Campistol JM.
    Transplantation; 2009 Apr 27; 87(8 Suppl):S19-22. PubMed ID: 19384182
    [Abstract] [Full Text] [Related]

  • 19. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 27; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 20. The role of mTOR inhibitors in the management of posttransplant malignancy.
    Monaco AP.
    Transplantation; 2009 Jan 27; 87(2):157-63. PubMed ID: 19155967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.